The Mind Blowing Science of Ibogaine: The Addiction Reset Button

Dr. Hyman Show Clips

1,304 views • 10 months ago Save 2 min 6 min read

Video Summary

The video delves into the complex mechanisms of how certain substances impact brain structure and function, leading to lasting changes. It explores their effects on neurotransmitter systems, neurotrophic factors that stimulate brain growth and connectivity, and the inhibition of the default mode network, which is associated with the ego and sense of separateness. These effects are observed across various conditions, including addiction, PTSD, depression, anxiety, and traumatic brain injury.

Further research highlights a unique mechanism involving gal derived neurotrophic factor (GDNF), which supports dopamine neuron health and appears to reverse addiction behaviors in animal models by restoring dopamine function and resetting the reward system. Human studies using EEG have shown a general physiological slowing of brain activity after treatment, correlating with symptom improvement and cognitive enhancement. This suggests a potential for tuning drug dosage based on individual brain activity, a concept already applied in anesthesia and now being explored in psychiatry.

The discussion contrasts these rapid, brain-focused interventions with traditional, lengthy talk therapies, emphasizing the need for psychiatric treatments that can match the speed of illness progression and disability. The promise lies in developing more immediate and effective therapeutic approaches that address the underlying biological mechanisms of mental health conditions.

Short Highlights

The substance's mechanism of action affects both brain structure and function, leading to lasting changes.
It impacts excitatory NMDA receptors, the serotonin system, and brain-derived neurotrophic factor (BDNF), promoting brain growth and neuroplasticity.
The treatment inhibits the default mode network, reducing feelings of separateness and fostering a sense of connection.
Research indicates it can restore dopamine function in the reward system, reversing addiction in animal models.
EEG studies show physiological slowing of brain activity post-treatment, correlating with symptom reduction and suggesting potential for dose tuning.

Key Details

Understanding the Mechanisms of Brain Impact [00:04]

The mechanism of action is still being deciphered but works on both the structure and function of the brain.
It appears to have lasting changes, not just in-the-moment effects.
For heroin addicts, it can eliminate addiction cravings and withdrawal symptoms, which is a physiological response, not psychological suppression.
In PTSD, it calms overexcited NMDA receptors, which are excitatory receptors that become overactive with trauma.
It affects the serotonin system and brain factors like BDNF (brain-derived neurotrophic factor).
BDNF stimulates brain growth, connectivity, neurogenesis, neuroplasticity, more brain cells, and more connections between brain cells, helping to repair and heal the brain.
It shows efficacy even in traumatic brain injury.
It inhibits the default mode network, similar to other psychedelics, which is associated with the ego and self-protection.
Suppressing the default mode network can quiet the sense of disconnection and separateness, allowing individuals to feel part of a greater whole.

This section focuses on the broad biological impacts of the substance, highlighting its multifaceted effects on brain health and psychological states, suggesting a wide range of therapeutic applications.

"It works on both the structure and the function of the brain. So, it doesn't just change it in the moment. Seems to have lasting changes."

Applications in Various Conditions and Mechanisms [01:48]

The speaker asks for an unpacking of the mechanisms and how they work in different disease states like PTSD, depression, anxiety, trauma, and brain injury.
A key mechanism unique to ibogaine is gal derived neurotrophic factor (GDNF).
GDNF is involved with dopamine neuron health and upregulates it.
A study with mice trained to self-administer alcohol showed that ibogaine could reverse this behavior, leading them to stop drinking.
Injecting GDNF into the ventral tegmental area (the dopamine-producing area involved in the reward system) produced the same effect as ibogaine, causing the mice to stop self-administering alcohol.
This suggests that at least the anti-addiction mechanism of ibogaine involves restoring dopamine function within the ventral tegmental area, resetting the reward system.

This part of the discussion pivots to specific applications, focusing on ibogaine's role in addiction treatment through its impact on the dopamine system and GDNF.

"And so it's probably that at least the anti-addiction mechanism of Ibeane is that it's restoring dopamine function within that um that vententral tegmental area in a way that resets the reward system."

EEG Findings and Potential for Dose Tuning [04:03]

A study published in Nature Mental Health examined EEG brain wave tests in participants who received ibogaine.
Tests were conducted before, after, and one month after treatment.
The study observed a general slowing of all the different power spectra of the EEG.
This physiological slowing of the brain after treatment correlated with the strength of the psychological effect (the trip).
It also correlated with the reduction in PTSD symptoms and improvement in cognition.
This is a first-step study, and more work is needed, but it suggests that EEG might be used to tune the drug dose to the physiology of the brain, rather than relying solely on subjective readouts.
This dose tuning could potentially optimize PTSD effects, with some individuals needing more or less of the substance.

This section details recent research using EEG to measure the physiological effects of ibogaine, opening up possibilities for more precise and personalized treatment.

"But also, interestingly, the reduction in PTSD symptoms and the improvement in cognition. And so, you know, that's it's a it's a first-step study."

Bridging Psychiatry and Neurology with Rapid Treatments [06:16]

The ability to understand and tune treatment based on brain physiology is considered useful.
There's a historical divide where neurologists focus on the brain and psychiatrists on the mind.
This approach examines psychiatry through the lens of the brain, moving beyond the mind-only focus of traditional psychoanalysis.
Traditional talk therapy and psychoanalysis can take many years (e.g., 20 years) for potential improvement.
In contrast, a single ibogaine journey might potentially address issues that would take 20 years of psychotherapy.
While more proof is needed, this speed difference is a significant point.
The problem in psychiatry is that treatments often take too long, not matching the speed of the illness and disability.
This can lead to individuals experiencing prolonged suffering while waiting for treatments to take effect, as seen with oral antidepressants that take time to work.

This final segment contrasts the rapid, brain-based interventions with traditional psychiatric approaches, highlighting the urgent need for treatments that can keep pace with the progression of mental health conditions.